- SpectronRx has expanded its Grissom Aeroplex campus to 34 acres, supporting around 200,000 square feet of GMP-aligned radiopharmaceutical manufacturing space.
- The expansion brings isotope production, development, scale-up, and GMP manufacturing together on a single site to support global clinical and commercial demand.
SpectronRx has announced a major expansion of its Grissom Aeroplex commercial manufacturing campus near Bunker Hill, Indiana, increasing its capacity to deliver therapeutic and diagnostic radiopharmaceutical doses at scale. The project adds 14 acres and a new 150,000-square-foot production facility, bringing the site to 34 acres and approximately 200,000 square feet of GMP-aligned manufacturing space.
The expanded campus consolidates isotope production, drug development, scale-up, and GMP manufacturing under one roof. SpectronRx said the site is designed for high-throughput production of radioligand therapy and diagnostic doses and can currently support more than 300,000 patient doses per year. The master plan allows for future expansion to more than one million square feet of production capacity.
“Radiopharmaceutical demand is rising faster than at any time in our industry’s history. The expansion is intended to ensure capacity, quality, and compliance keep pace with partner growth.”
John Zehner, Chief Executive Officer of SpectronRx
The Grissom Aeroplex campus strengthens SpectronRx’s global supply reach through proximity to a 24/7 general-aviation airport, access to major cargo hubs, and location within a 12-hour drive of more than 60% of the US population. GMP operations comply with 21 CFR Parts 211 and 212, Annex 1, and other applicable international requirements, supported by redundant power, isolated production suites, and advanced radiation handling technologies.
Beyond Indiana, SpectronRx operates GMP-compliant facilities in South Bend and Indianapolis, Indiana; Danbury, Connecticut; and Belgium. The company said its CDMO and contract manufacturing model focuses exclusively on supporting partner programmes across radiopharmaceutical and isotope development, from early-stage work through commercial distribution.
